Changes in Hong Kong stocks | Nuochengjianhua (09969) rose more than 4%, and strong commercial product growth combined with BD turned a year-on-year loss into profit in the first half of the year

The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose more than 4%. As of press release, it had risen 4.21% to HK$14.37, with a turnover of HK$50,133 million.

According to the news, Nuochengjianhua announced the 2026 interim results, with revenue of about 1,137 million yuan, an increase of 55.46%; adjusted profit of about 277 million yuan, turning a year-on-year loss into a profit; and profit attributable to the owner of the parent company was about 246 million yuan, turning a year-on-year loss into a profit. Revenue growth was mainly due to strong growth in commercial products and the achievement of milestone values in global BD projects. Drug revenue in the first half of the year reached 920 million yuan, up 43.2% year on year, mainly due to continued rapid growth in obutinib and revenue from new contributions from tamxitumab and zoletriptinib.

The announcement stated that during the reporting period, Nuochengjianhua further promoted its multi-product and multi-field strategy, and continued to expand its contribution in the fields of hematologic tumors, autoimmune diseases and solid tumors. A number of assets have reached or have reached key regulatory and clinical milestones, laying a solid foundation for continued long-term growth.